<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132817">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899378</url>
  </required_header>
  <id_info>
    <org_study_id>SPO109949</org_study_id>
    <nct_id>NCT01899378</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Probiotics in Bangladeshi Infants</brief_title>
  <official_title>Safety and Efficacy of Probiotics in Bangladeshi Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrheal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Bangladesh: Ethical Review Committee and Data Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Here the investigators propose to preliminarily investigate the safety and effects of
      probiotics in infants in Bangladesh through a pilot randomized clinical trial.  The
      investigators hypothesize that two probiotics are safe for infants in Bangladesh and may
      have an effect on biomarkers of gut health and immunity.  The specific aims of this pilot
      are: i) to confirm the safety of administering probiotic strains to infants in low-income
      countries, ii) to determine the effects of dosing frequency on colonization and persistence
      of probiotics in the GI tract, iii) to measure markers of intestinal and immune function and
      microbiota structure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Presence of probiotic in the stool</measure>
    <time_frame>weeks 0-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>presence of absence of each probiotic in the stool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantity of probiotic in the stool</measure>
    <time_frame>weeks 0-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>amount of each probiotic present in the stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composition of microbiota</measure>
    <time_frame>weeks 0-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>microbial community composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical effects</measure>
    <time_frame>daily for 7 days after first probiotic administration, then weeks 2-12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>fever, diarrhea, wheezing, rash, stool frequency, feeding frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut function</measure>
    <time_frame>months 0, 1, 2, 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>lactulose/mannitol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut inflammation</measure>
    <time_frame>months 0,1,2,3</time_frame>
    <safety_issue>No</safety_issue>
    <description>fecal neopterin, alpha-1 antitrypsin, and myeloperoxidase - correlated with future growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut inflammation/translocation</measure>
    <time_frame>months 0, 1, 2, 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>IL22, CD-14, total IgG and c-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>growth</measure>
    <time_frame>month 0, 1, 2, 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>weight, length, head circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breastfeeding rates</measure>
    <time_frame>month 0, 1, 2, 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>daily probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>weekly probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bi-weekly probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>10^8 CFU</description>
    <arm_group_label>daily probiotic</arm_group_label>
    <arm_group_label>weekly probiotic</arm_group_label>
    <arm_group_label>bi-weekly probiotic</arm_group_label>
    <other_name>BioGaia Protectis Baby</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum infantis</intervention_name>
    <description>10^9 CFU</description>
    <arm_group_label>daily probiotic</arm_group_label>
    <arm_group_label>weekly probiotic</arm_group_label>
    <arm_group_label>bi-weekly probiotic</arm_group_label>
    <other_name>Align</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants.

          -  Infants 1 -3 months of age at the beginning of the study.

          -  Parents/guardians of each subject are able to understand study procedures and agree
             to participate in the study by giving consent.

          -  Parents and child are planning to remain in Dhaka for the next four months.

        Exclusion Criteria:

          -  Infants with known birth defects.

          -  Infants who have been hospitalized.

          -  Infants who have an acute infection or illness at the time of enrolment.

          -  Infants who are currently taking antibiotics

          -  Infants &lt;1 month of age or &gt;3 months of age.

          -  Infants three standard deviations below mean on anthropometric measures (will be
             referred for medical care).

          -  Infants who are already receiving a probiotic product or treatment.

          -  A diagnosis or suspicion of immunodeficiency disorder.

          -  A diagnosis or suspicion of bleeding disorder that would contraindicate venipuncture.

          -  Family residence outside of Dhaka or families expecting to move outside of Dhaka in
             the next 4 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yana Emmy E Hoy-Schulz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Parsonnet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Luby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leanne Unicomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Center for Diarrheal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaniz Jannat, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>International Center for Diarrheal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yana Emmy Hoy-Schulz, PhD</last_name>
    <phone>9129960603</phone>
    <email>ehoy@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Parsonnet, MD</last_name>
    <email>parsonnt@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>International Center for Diarrheal Disease Research, Bangladesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Unicomb, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Leanne Unicomb, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaniz Jannat, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulfalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
